CareDx, Inc. - Common Stock (OQ:CDNA)

Jun 03, 2024 07:05 am ET
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced in conjunction with the 2024 American Transplant Congress, the publication in Nature Medicin
May 30, 2024 07:05 am ET
AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data to be presented at the 2024 American Transplant Congress (ATC) being held June 1-5 in Philadelphia.
Apr 19, 2024 04:05 pm ET
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 15, 2024, CareDx granted an option to purchase 700,706 shares of CareDx’s common stock (the “Inducement Option”) and 487,804 restricted stock units (the “Inducement RSUs” ) to John Hanna, CareDx’s newly appointed President and Chief Executive Officer. The Inducement Option and the Inducement RSUs were approved
Apr 16, 2024 04:02 pm ET
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company’s Board of Directors, effective April 15, 2024.
Apr 09, 2024 07:00 am ET
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx and study collaborators will be presenting the latest data featuring CareDx’s cardiothoracic portfolio at the International Society for Heart and Lung Transplantation (ISHLT) 44th Annual Meeting & Scientific Sessions, taking place from April 10-13 in Prague, Czech Republic.
Mar 11, 2024 04:10 pm ET
CareDx Appoints Bryan Riggsbee to Its Board of Directors
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that Bryan Riggsbee joins CareDx’s Board of Directors, effective March 11, 2024.
Feb 28, 2024 04:05 pm ET
CareDx Announces Fourth Quarter and Full Year 2023 Financial Results
CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2023.
Feb 27, 2024 04:05 pm ET
CareDx to Participate in the Raymond James & Associates’ 45th Annual Institutional Investors Conference
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the company will be participating in the upcoming Raymond James & Associates’ 45th Annual Institutional Investors Conference.
Feb 21, 2024 04:05 pm ET
CareDx to Report Fourth Quarter and Full Year 2023 Financial Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Feb 21, 2024 07:00 am ET
CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings
CareDx, Inc. (Nasdaq: CDNA) —The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that it will be showcasing the breadth of its specialized digital solutions and the latest advancements in its cellular therapy and transplant monitoring pipeline at the 2024 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, being held February 21-25 in San Antonio, Texas
Jan 26, 2024 09:45 pm ET
CareDx Issues Statement in Patent Infringement Case
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the jury verdict in the patent litigation brought by Natera, Inc. (Nasdaq: NTRA).
Jan 11, 2024 04:05 pm ET
CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence and the fifth consecutive year as the Distinguished Founder’s Circle Sponsor for the Annual American Society of Transplant Surgeons (ASTS) Winter Symposium being held January 11 - 14, 2024 in Miami, Florida.
Jan 09, 2024 07:00 am ET
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported preliminary financial results for the fourth quarter and full year ended December 31, 2023.
Dec 19, 2023 07:00 am ET
CareDx Joins Forces with the National Foundation for Transplants to Improve Post-Transplant Medication Adherence
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is joining forces with the National Foundation for Transplants (NFT) in offering its Transplant Pharmacy services to NFT patient members to help them manage the complexity of post-transplant medication adherence.
Nov 08, 2023 04:05 pm ET
CareDx Reports Third Quarter 2023 Results
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today reported financial results for the third quarter ended September 30, 2023.
Nov 02, 2023 04:05 pm ET
CareDx to Report Third Quarter 2023 Financial Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the third quarter 2023 after market close on Wednesday, November 8th, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Nov 01, 2023 04:02 pm ET
CareDx Announces CEO Transition
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced today that Dr. Reginald Seeto will be stepping down from his position as Chief Executive Officer and President and resigning as a Director of the Board effective November 1, 2023, and will transition to the role of Senior Advisor to the Chairperson.
Oct 17, 2023 07:00 am ET
CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual Meeting
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 49th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) being held in San Antonio, Texas from October 16-20, 2023.
Oct 03, 2023 06:00 pm ET
CareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed Patents
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – acknowledges the Supreme Court’s decision not to review the Federal Circuit’s decision on the patent eligibility of three Stanford-licensed patents. CareDx notes the decision does not impact the Company’s ability to continue providing AlloSure® donor-derived cell-free DNA (dd-cfDNA).
Sep 19, 2023 07:00 am ET
CareDx To Present at the 2023 Cantor Global Healthcare Conference
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the 2023 Cantor Global Healthcare Conference.
Sep 14, 2023 02:00 am ET
CareDx Advances Global Transplant Patient Care at ESOT Congress 2023
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 European Society for Organ Transplantation (ESOT) Congress taking place September 17-20, 2023, in Athens, Greece.
Aug 31, 2023 07:00 am ET
CareDx To Present at the H.C. Wainwright 25th Annual Global Investment Conference
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference.
Aug 17, 2023 07:00 am ET
CareDx Hosts Second Annual MEET Digital Health User Conference to Showcase Latest Innovations to Enhance Transplant Patient Care
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its second annual digital health user conference, the Management Expert Exchange in Transplantation (MEET) Conference, taking place August 27-29 in Dallas, Texas.
Aug 11, 2023 07:00 am ET
CareDx Comments on Issuance of Proposed LCD for Molecular Testing for Solid Allograft Rejection
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today commented on the issuance of proposed changes to the Local Coverage Determination (LCD) MolDX Molecular Testing for Solid Organ Allograft Rejection that covers AlloSure®, AlloMap® and HeartCare.
Aug 08, 2023 04:05 pm ET
CareDx Reports Second Quarter 2023 Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the second quarter ended June 30, 2023.
Aug 07, 2023 11:08 am ET
CareDx Announces District Court Judge Bars Natera from Falsely Advertising and Overstating the Scientific Performance of its Prospera Transplant Test
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the United States District Court for the District of Delaware (the “District Court”) issued an injunction prohibiting Natera (Nasdaq: NTRA) from continuing to falsely advertise and overstate the scientific performance of its Prospera transplant test. A copy of the injunction is available
Aug 03, 2023 07:00 am ET
CareDx to Report Second Quarter 2023 Financial Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2023 after market close on Tuesday, August 8th, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Aug 02, 2023 07:00 am ET
CareDx’s HeartCare Multimodality Service Receives Medicare Coverage for Heart Transplant Surveillance
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced Medicare coverage for HeartCare, a multimodality testing service that includes both AlloMap® Heart and AlloSure® Heart, in a given patient encounter, for heart transplant surveillance. Coverage is effective April 1, 2023. AlloMap Heart and AlloSure Heart are also covered by Medicare individually.
Jul 25, 2023 07:00 am ET
CareDx Acquires MediGO, an Organ Transplant Supply Chain and Logistics Company
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the acquisition of MediGO, Inc. in a strategic move to expand its digital health portfolio to serve the organ procurement organization (OPO) market while also bolstering its pre-transplant offerings aimed at shortening transplant wait times and increasing access to donated organs.
Jul 17, 2023 11:42 pm ET
CareDx Applauds District Court Decision to Uphold Jury Verdict that Natera Falsely Advertised its Prospera Transplant Test
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the United States District Court for the District of Delaware (the “District Court”) decision upheld and reaffirmed the March 2022 jury verdict finding that Natera (Nasdaq: NTRA) violated the Lanham Act by falsely advertising the scientific performance of its Prospera transplant test.
Jul 11, 2023 07:00 am ET
CareDx’s AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx’s AlloSure® Lung donor-derived cell-free DNA (dd-cfDNA) molecular testing service has received Medicare coverage.
Jun 01, 2023 08:00 am ET
CareDx Demonstrates Innovation Leadership at 2023 Transplant Congress
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 American Transplant Congress (ATC) with 65 scientific presentations. CareDx will also be hosting a satellite symposium1 and sponsoring the Women’s Networking Event. The ATC meeting takes place June 3-7 in San Diego, California.
Jun 01, 2023 07:00 am ET
CareDx to Participate in Upcoming Investor Conferences
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences.
May 24, 2023 08:00 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of CareDx, Inc. and Encourages Long-Term CDNA Stockholders to Contact the Firm
Kaskela Law LLC announces that it is investigating CareDx, Inc. (“CareDx”) (NASDAQ: CDNA) on behalf of the Company’s long-term stockholders. Recently a shareholder class action complaint was filed against CareDx on behalf of certain investors who...
May 16, 2023 07:00 am ET
CareDx Showcases Digital Health Portfolio at 31st Annual UNOS Transplant Management Forum
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will showcase its digital health portfolio and host a symposium which addresses barriers in access to transplantation at the 31st Annual UNOS Transplant Management Forum (TMF) taking place May 16-18 in Denver, Colorado. CareDx is the leading Diamond level sponsor of this year’s UNOS TMF.
May 10, 2023 04:05 pm ET
CareDx Reports First Quarter 2023 Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the first quarter ended March 31, 2023.
May 08, 2023 07:01 am ET
CareDx to Report First Quarter 2023 Financial Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 10, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Apr 25, 2023 06:01 am ET
CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will showcase the latest developments across its AlloSeq®* portfolio during the 36th European Immunogenetics and Histocompatibility Conference taking place April 26-29 in Nantes, France.
Apr 19, 2023 09:00 am ET
SHAREHOLDER ALERT: Morris Kandinov Investigating LFST, BRY, CDNA, and OPEN; Shareholders are Encouraged to Contact the Firm
National law firm Morris Kandinov is investigating the actions of the officers and board of directors of LifeStance Health Group, Inc., Berry Corporation, CareDx, Inc., and Opendoor Technologies Inc. If you are a current owner of shares of any of...
Apr 19, 2023 07:01 am ET
CareDx Showcases Leadership with Over 55 Oral Presentations and Posters at the 43rd Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation
“We are exceedingly proud to have a remarkable presence at this year’s ISHLT meeting with HeartCare data showing significant clinical benefits and compelling data supporting the advancement of AlloSure Lung into clinical practice,” said Reg Seeto, CEO and President of CareDx. “The significant body of evidence presented at ISHLT demonstrates the value of routinely incorporating CareDx’s non-invasive molecular solutions in heart and lung transplant clinical decision making.”
Apr 06, 2023 07:01 am ET
National Kidney Foundation Honors CareDx with Corporate Citizenship Award for its Commitment to the Transplant Community
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the National Kidney Foundation honored CareDx with a corporate citizenship award during its 41st Annual Kidney Ball held on March 31, 2023, in Washington, D.C.
Apr 05, 2023 06:55 am ET
CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation
CareDx, Inc. (Nasdaq: CDNA) and Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO) – today announced an exclusive partnership aimed at advancing the next wave of innovation using fully transplantable human bioengineered organs.
Apr 05, 2023 06:50 am ET
CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation
CareDx, Inc. (Nasdaq: CDNA) and Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO) -- today announced an exclusive partnership aimed at advancing the next wave of innovation using fully transplantable human bioengineered organs. CareDx will...
Mar 23, 2023 07:01 am ET
CareDx Presents Latest Advancements at 12th Congress of the International Pediatric Transplant Association
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its gold-level sponsorship and participation at the 12th Congress of the International Pediatric Transplant Association (IPTA) taking place March 25-28, 2023, in Austin, Texas.
Mar 10, 2023 10:50 pm ET
CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into CareDx, Inc. (NasdaqGM: CDNA).
Mar 07, 2023 07:01 am ET
The American Society of Transplant Surgeons Position Statement Supports Use of CareDx’s AlloSure Kidney for Organ Transplant Surveillance
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the issuance of a new position statement by the American Society of Transplant Surgeons (ASTS) supporting the use of CareDx’s AlloSure® Kidney for organ transplant surveillance, and AlloSure Heart and AlloMap® Heart.
Mar 06, 2023 04:32 pm ET
CareDx Update Regarding Raymond James & Associates’ Conference
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company has determined not to participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference scheduled for later today in light of scheduling conflicts. The company looks forward to providing its next corporate update in the near term.
Mar 06, 2023 07:01 am ET
CareDx To Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference.
Mar 03, 2023 07:01 am ET
CareDx Comments on MolDX Publication of New Billing and Coding Article
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today commented on the release of a Billing Article related to MolDX Molecular Testing for Solid Organ Allograft Rejection that covers AlloSure® and AlloMap®. The Billing Article is effective March 31, 2023.
Mar 01, 2023 07:01 am ET
CareDx Key Supporter of the National Kidney Foundation’s Annual Kidney Patient Summit
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced that it is sponsoring the National Kidney Foundation (NKF) Annual Kidney Patient Summit taking place on Capitol Hill on March 1-2, 2023.
Feb 27, 2023 04:01 pm ET
CareDx Reports Fourth Quarter and Full Year 2022 Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the fourth quarter and full year ended December 31, 2022.
Feb 24, 2023 09:50 pm ET
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
NEW ORLEANS, Feb. 24, 2023 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into CareDx, Inc. (NasdaqGM: CDNA).  
Feb 22, 2023 07:01 am ET
CareDx Showcases Clinical Value of Multimodality and AI Innovation at the American Society of Transplantation Cutting Edge of Transplantation Meeting
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced that it is showcasing the clinical value of multimodality and artificial intelligence innovation at the annual American Society of Transplantation Cutting Edge of Transplantation (CEoT) meeting taking place February 23-25, in Scottsdale, Arizona.
Feb 21, 2023 04:01 pm ET
CareDx to Report Fourth Quarter and Full Year 2022 Financial Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2022 after market close on Monday, February 27, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Feb 16, 2023 07:01 am ET
CareDx Showcases Latest Advancements in Cellular Transplant and Therapy Including Specialized Digital Health Solutions at the 2023 Tandem Meetings
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced that it will be presenting its latest solutions to support the cellular transplant and therapy ecosystem at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® taking place February 15-19 in Orlando, Florida.
Feb 13, 2023 10:54 am ET
CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into CareDx, Inc. (NasdaqGM: CDNA).
Jan 26, 2023 07:01 am ET
JACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Journal of the American College of Cardiology (JACC): Heart Failure has published a
Jan 11, 2023 07:01 am ET
CareDx Fosters Transplant Innovation as Distinguished Founder’s Circle Sponsor for the 23rd Annual American Society of Transplant Surgeons State of the Art Winter Symposium
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced its leading participation and top spot, for the fourth consecutive year, as a Distinguished Founder’s Circle Sponsor for the 23rd Annual ASTS (American Society of Transplant Surgeons) State of the Art Winter Symposium, taking place January 12-15, in Miami, Florida.
Jan 09, 2023 07:00 am ET
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported preliminary financial results for the fourth quarter and full year ended December 31, 2022.
Dec 30, 2022 10:50 pm ET
CAREDX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CareDx, Inc. - CDNA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into CareDx, Inc. (NasdaqGM: CDNA).
Dec 21, 2022 06:00 pm ET
New ISHLT Guidelines Support Use of CareDx’s HeartCare Solutions, AlloMap and AlloSure, in Routine Monitoring of Heart Transplant Patients
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication1 of new guidelines by the International Society for Heart and Lung Transplantation (ISHLT) supporting the use of CareDx’s non-invasive molecular surveillance portfolio.
Dec 16, 2022 09:50 pm ET
CAREDX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CareDx, Inc. - CDNA
NEW ORLEANS, Dec. 16, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into CareDx, Inc. (NasdaqGM: CDNA).
Dec 14, 2022 07:00 am ET
Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Grace E. Colón, Ph.D., to its Board of Directors. Dr. Colón has more than 25...
Dec 06, 2022 08:01 am ET
CareDx Announces $50 Million Stock Repurchase Program
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that its Board of Directors has authorized a common stock repurchase program of up to $50 million of shares over a period of up to 24 months.
Dec 05, 2022 06:30 pm ET
CAREDX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CareDx, Inc. - CDNA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into CareDx, Inc. (NasdaqGM: CDNA).
Dec 01, 2022 08:15 am ET
Independent Prospective Study Defines Reference Range for CareDx’s AlloSure for Long-Term Lung Transplant Surveillance
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the results of a new study published in Transplantation Direct1 which establishes a reference baseline when using AlloSure® Lung in the long-term surveillance of lung transplant patients.
Nov 11, 2022 07:01 am ET
CareDx Committed to Delivering Clinical Innovation to the Transplant Patient and Physician Community
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the five-year anniversary of AlloSure®, the groundbreaking, non-invasive donor-derived cell-free DNA (dd-cfDNA) surveillance solution used to measure allograft injury in solid organ transplant recipients. AlloSure along with AlloMap® represent disruptive innovations in the field of solid organ transplant.
Nov 04, 2022 07:00 am ET
CareDx To Participate in Upcoming Investor Conferences
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences.
Nov 03, 2022 04:01 pm ET
CareDx Reports Third Quarter 2022 Results
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today reported financial results for the third quarter ended September 30, 2022.
Nov 02, 2022 07:01 am ET
CareDx Demonstrates Power of AlloSure and Digital Health Transplant Solutions at American Society of Nephrology Kidney Week
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will be sharing the latest data on AlloSure® Kidney and its patient-centered digital health solutions at the American Society of Nephrology (ASN) Kidney Week 2022 meeting being held November 3 - 6 in Orlando, Florida.
Nov 01, 2022 07:01 am ET
Independent Longitudinal Study Finds CareDx’s AlloSure Detects Early Signs of Rejection in Pediatric Kidney Transplant Patients
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the results of a new study published in the Clinical Journal of the American Society of Nephrology (CJASN)1 showing that CareDx’s AlloSure® Kidney donor-derived cell-free DNA (dd-cfDNA) solution identifies early signs of allograft rejection and BK virus infection in pediatric kidney transplant patients.
Oct 27, 2022 07:01 am ET
CareDx Congratulates C-Path's Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today congratulates C-Path’s Transplant Therapeutics Consortium and the Paris Transplant Group for their leadership in gaining European Medicine Agency (EMA) draft qualification1 for the iBox® Scoring System as a secondary endpoint in kidney transplant clinical trials.
Oct 26, 2022 07:30 am ET
CareDx to Report Third Quarter 2022 Financial Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the third quarter 2022 after market close on Thursday, November 3, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Oct 26, 2022 07:01 am ET
CareDx Joins Forces with National Kidney Foundation and Honor the Gift Coalition to Host Immuno Bill Webinar for Kidney Transplant Patients
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx is hosting a webinar with the National Kidney Foundation and Honor the Gift Coalition to help patients navigate Medicare enrollment associated with the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020. Often referred to as the "Immuno Bill", the Bill becomes effective January 1, 2023.
Oct 25, 2022 07:01 am ET
CareDx Presents Latest Data on AlloSeq NGS Solutions and Transplant Innovation at the American Society for Histocompatibility and Immunogenetics Annual Meeting
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its leading presence as a Diamond Level sponsor at the 48th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) being held in Las Vegas, Nevada from October 24 to October 28.
Sep 29, 2022 07:01 am ET
CareDx to Host Symposium Covering Innovation in Multimodal Surveillance Including AiCAV for Post-Cardiac Transplant Care
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will host a symposium to describe the latest innovations in post-cardiac transplant care at the HFSA (Heart Failure Society of America) Annual Scientific Meeting 2022 taking place in Washington, D.C., September 30 - October 3.
Sep 27, 2022 12:32 pm ET
CareDx, Inc. Investor News: Robbins LLP is Investigating CareDx, Inc. (CDNA) on Behalf of Shareholders
Shareholder rights law firm Robbins LLP is investigating CareDx, Inc. (NASDAQ: CDNA) and its officers and directors to determine if they breached their fiduciary duties and violated securities laws by engaging in improper schemes to inflate...
Sep 27, 2022 07:01 am ET
Transplant Patients Experience Less Pain and Fewer Adverse Events with CareDx Non-Invasive Testing Solutions
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a new peer-reviewed publication showing that AlloMap®, the industry’s only gene-expression profiling (GEP) blood test to non-invasively assess graft rejection by monitoring immune quiescence in heart transplant patients,1 resulted in less pain and fewer adverse events compared to heart biopsy.2 The study also highlights that the as
Sep 26, 2022 08:43 am ET
CareDx Congratulates Board Member Dr. Grace Colón for Being Named Healthcare Innovator on Top 50 Most Powerful Latinas List
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Dr. Grace Colón, a member of its Board of Directors, has been named on the 2022 Most Powerful Latinas list by The Association of Latino Professionals For America (ALPFA).
Sep 19, 2022 07:01 am ET
CareDx Showcases Transplant Digital Leadership in Patient Care at 2022 MEET Conference
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is convening its annual digital health user conference, Management Expert Exchange in Transplantation (MEET), September 18-20 in Las Vegas, Nevada.
Sep 14, 2022 07:01 am ET
CareDx Celebrates 1 Million Organ Transplants and 100,000 Patient Milestone
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has served its 100,000th transplant patient, representing one out of ten patients transplanted in the U.S. This milestone demonstrates strong clinical adoption of molecular surveillance for transplant patients and showcases AlloMap® and AlloSure® as leading tools which are becoming firmly embedded in post-transplant patient care.
Sep 12, 2022 07:01 am ET
CareDx Demonstrates Global Leadership at 29th International Congress of The Transplantation Society
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its leading participation in the 29th International Congress of The Transplantation Society (TTS 2022) taking place September 10-14 in Buenos Aires, Argentina.
Aug 11, 2022 07:01 am ET
CareDx and MOTTEP Co-Host Health Equity Summit
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will co-host, along with MOTTEP (Minority Organ Tissue Transplantation Education Program), a panel discussion, “Tackling Health Equity in Organ Transplantation,” on August 18, 2022, 10:00-11:00am PST (1:00–2:00pm EST). The event is timed in recognition of National Minority Donor Awareness Month.
Aug 04, 2022 04:01 pm ET
CareDx Reports Second Quarter 2022 Results
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today reported financial results for the second quarter ended June 30, 2022.
Aug 04, 2022 07:01 am ET
CareDx Unveils New Patient-Centered Medication Management Features on AlloCare Mobile Health App
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that its AlloCare® mobile health app features expanded medication adherence and patient-provider communication capabilities resulting from the successful integration of MedActionPlan®, an acquisition made last year.
Aug 02, 2022 07:01 am ET
CareDx Launches Personalized AlloHome Patient Monitoring Solution to Augment Pre- and Post-Transplant Care
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the availability of AlloHome™, a pan-organ patient monitoring solution that extends care into a patient’s home by capturing a range of vital health data that can help doctors with the early identification of adverse clinical events and the ability to make preemptive measures to avoid complications pre- and post-transplantation.
Jul 28, 2022 08:00 am ET
CareDx to Report Second Quarter 2022 Financial Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 4, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Jul 26, 2022 09:49 am ET
Investigation Alert HMBL, OKTA, CDNA: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors’ Losses?
HUMBL, Inc. (OTC: HMBL) Johnson Fistel, LLP is investigating potential claims on behalf of HUMBL, Inc. (OTC: HMBL) against certain of its officers and directors. If you have continuously owned HUMBL shares before November 2020, you can click or...
Jul 22, 2022 10:53 am ET
Final Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Reminds CareDx, Inc. (CDNA) Shareholders of Last Few Hours to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA) and certain of its officers, on behalf of all persons and...
Jul 22, 2022 05:45 am ET
CDNA SHAREHOLDER ALERT: Jakubowitz Law Reminds CareDx Shareholders of a Lead Plaintiff Deadline of July 22, 2022
NEW YORK, July 22, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of CareDx, Inc. (NASDAQ: CDNA).
Jul 21, 2022 01:00 pm ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CareDx, Inc. (CDNA)
The Law Offices of Frank R. Cruz reminds investors of the upcoming July 22, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ:
Jul 21, 2022 08:49 am ET
Final Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed against CareDx, Inc. (CDNA)
RADNOR, Pa., July 21, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against CareDx, Inc. ("CareDx") (NASDAQ: CDNA). The action charges CareDx with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of CareDx's materially misleading statements and omissions to the public, CareDx's investors have suffered significant losses.
Jul 21, 2022 05:45 am ET
CDNA LAWSUIT ALERT: Levi & Korsinsky Notifies CareDx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, July 21, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA) of a class action securities lawsuit.
Jul 20, 2022 09:50 pm ET
CAREDX 48 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against CareDx, Inc.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2022 to file lead plaintiff applications in a securities class action lawsuit against CareDx, Inc. (“CareDx” or the “Company”) (NasdaqGM: CDNA), if they purchased the Company’s shares between February 24, 2021 and May 5, 2022, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Jul 20, 2022 09:00 pm ET
CAREDX DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against CareDx, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired CareDx securities between February 24, 2021 and May 5, 2022, both dates inclusive (the “Class Period”). Investors have until July 22, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Jul 20, 2022 11:00 am ET
DEADLINE ALERT for CDNA, SPRO, LMPX, IONQ: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 20, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of CareDx, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 22, 2022 - (NASDAQ: CDNA)
NEW YORK, July 20, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of CareDx, Inc..
Jul 19, 2022 11:13 pm ET
CAREDX SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against CareDx, Inc. - CDNA
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 22, 2022 to file lead plaintiff applications in a securities class action lawsuit against CareDx, Inc. (“CareDx” or the “Company”) (NasdaqGM: CDNA), if...
Jul 19, 2022 12:30 pm ET
CareDx, Inc. (NASDAQ: CDNA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors With Losses in Excess of $100,000 of the Deadline to File a Lead Plaintiff Motion in a Securities C
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Jul 19, 2022 12:00 pm ET
CDNA Investors Have Opportunity to Lead CareDx, Inc. Securities Fraud Lawsuit
BENSALEM, Pa., July 19, 2022 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA).
Jul 19, 2022 11:00 am ET
Bronstein, Gewirtz & Grossman, LLC Reminds CareDx, Inc. (CDNA) Shareholders of July 22, 2022 Class Action Deadline and Encourages Investors to Actively Participate
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired CareDx securities between February 24, 2021, and May 5, 2022, (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Jul 19, 2022 05:45 am ET
CDNA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 22, 2022 in the Class Action Filed on Behalf of CareDx, Inc. Shareholders
NEW YORK, July 19, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CareDx, Inc. (NASDAQ: CDNA) alleging that the Company violated federal securities laws.
Jul 18, 2022 01:23 pm ET
CDNA 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages CareDx (CDNA) Investors with Significant Losses to Contact Firm’s Attorneys, Application Deadline Approaching in Securiti
Hagens Berman urges CareDx, Inc. (NASDAQ: CDNA) investors to with significant losses to submit your losses now. Class Period: Feb. 24, 2021 – May 5, 2022Lead Plaintiff Deadline: July 22, 2022Visit: www.hbsslaw.com/investor-fraud/CDNA Contact An...
Jul 18, 2022 11:45 am ET
DEADLINE ALERT for CDNA, SPRO, and LMPX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 18, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind CareDx Investors of a Lead Plaintiff Deadline of July 22, 2022
NEW YORK, July 18, 2022 /PRNewswire/ -- Attention CareDx, Inc. ("CareDx") (NASDAQ: CDNA) shareholders:
Jul 16, 2022 11:15 am ET
CDNA FINAL DEADLINE NOTICE: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages CareDx, Inc. Investors with Losses to Secure Counsel Before Important July 22 Deadline in Securities Class Action – C
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CareDx, Inc. (NASDAQ: CDNA) between February 24, 2021 and May 5, 2022, both dates inclusive (the “Class Period”), of the important July 22, 2022 lead...
Jul 15, 2022 10:50 pm ET
CAREDX SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against CareDx, Inc. - CDNA
NEW ORLEANS, July 15, 2022 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 22, 2022 to file lead plaintiff applications in a securities class action lawsuit against CareDx, Inc. ("CareDx" or the "Company") (NasdaqGM: CDNA), if they purchased the Company's shares between February 24, 2021 and May 5, 2022, inclusive (the "Class Period").  This action is pending in the United States District Court for the Northern District of California.
Jul 15, 2022 08:49 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CareDx, Inc. (NASDAQ: CDNA), Spero Therapeutics, Inc. (NASDAQ: SPRO), LMP...
Jul 15, 2022 01:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CareDx, Inc. (CDNA)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 22, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired CareDx, Inc. (“CareDx” or the...
Jul 15, 2022 05:45 am ET
CDNA SHAREHOLDER ALERT: Jakubowitz Law Reminds CareDx Shareholders of a Lead Plaintiff Deadline of July 22, 2022
NEW YORK, July 15, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of CareDx, Inc. (NASDAQ: CDNA).
Jul 14, 2022 01:00 pm ET
DEADLINE ALERT for CDNA, SPRO, LMPX, IONQ: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 14, 2022 05:45 am ET
CDNA LAWSUIT ALERT: Levi & Korsinsky Notifies CareDx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, July 14, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA) of a class action securities lawsuit.
Jul 13, 2022 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of CareDx, Inc. - CDNA
CEDARHURST, N.Y., July 13, 2022 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of CareDx, Inc. (NasdaqGM: CDNA), if they purchased the Company's shares between shares between February 24, 2021 and May 5, 2022, inclusive (the "Class Period"). Shareholders have until July 22, 2022 to file lead plaintiff applications in the securities class action lawsuit.
Jul 13, 2022 06:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CareDx, Inc. - CDNA
NEW YORK, July 13, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 13, 2022 11:37 am ET
CareDx, Inc. Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds CDNA Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf
RADNOR, Pa., July 13, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against CareDx, Inc. ("CareDx") (NASDAQ: CDNA). The action charges CareDx with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of CareDx's materially misleading statements and omissions to the public, CareDx's investors have suffered significant losses.
Jul 13, 2022 10:43 am ET
ENSV & CDNA Class Actions: Bronstein, Gewirtz & Grossman, LLC, A Leading Class Action Firm, Reminds Investors to Contact the Firm and Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jul 13, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of CareDx, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 22, 2022 - (NASDAQ: CDNA)
NEW YORK, July 13, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of CareDx, Inc..
Jul 12, 2022 10:50 pm ET
CAREDX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Car
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2022 to file lead plaintiff applications in a securities class action lawsuit against CareDx,...
Jul 12, 2022 04:00 pm ET
CareDx, Inc. (NASDAQ: CDNA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors With Losses in Excess of $100,000 of the Deadline to File a Lead Plaintiff Motion in a Securities C
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Jul 12, 2022 12:00 pm ET
CDNA Investors Have Opportunity to Lead CareDx, Inc. Securities Fraud Lawsuit
LOS ANGELES, July 12, 2022 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA).
Jul 12, 2022 11:45 am ET
DEADLINE ALERT for CDNA, SPRO, and LMPX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 12, 2022 05:45 am ET
CDNA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 22, 2022 in the Class Action Filed on Behalf of CareDx, Inc. Shareholders
NEW YORK, July 12, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CareDx, Inc. (NASDAQ: CDNA) alleging that the Company violated federal securities laws.
Jul 11, 2022 03:24 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages CareDx (CDNA) Investors with Significant Losses to Contact Firm’s Attorneys, July 22nd Deadline Approaching in Securities Class Action
Hagens Berman urges CareDx, Inc. (NASDAQ: CDNA) investors to with significant losses to submit your losses now. Class Period: Feb. 24, 2021 – May 5, 2022Lead Plaintiff Deadline: July 22, 2022Visit: www.hbsslaw.com/investor-fraud/CDNA Contact An...
Jul 11, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind CareDx Investors of a Lead Plaintiff Deadline of July 22, 2022
NEW YORK, July 11, 2022 /PRNewswire/ -- Attention CareDx, Inc. ("CareDx") (NASDAQ: CDNA) shareholders:
Jul 10, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CareDx, Inc. (NASDAQ: CDNA), Spero Therapeutics, Inc. (NASDAQ: SPRO), LMP...
Jul 10, 2022 08:17 pm ET
Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against CareDx, Inc. and Encourages Investors to Contact the Firm
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against CareDx, Inc. (“CareDx”)...
Jul 10, 2022 02:47 pm ET
ROSEN, NATIONAL TRIAL LAWYERS, Encourages CareDx, Inc. Investors with Losses to Secure Counsel Before Important July 22 Deadline in Securities Class Action – CDNA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CareDx, Inc. (NASDAQ: CDNA) between February 24, 2021 and May 5, 2022, both dates inclusive (the “Class Period”), of the important July 22, 2022 lead...
Jul 09, 2022 01:49 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CareDx, Inc. – CDNA
Pomerantz LLP is investigating claims on behalf of investors of CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980. The...
Jul 08, 2022 02:13 pm ET
DEADLINE ALERT for CDNA, SPRO, LMPX, IONQ: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 06, 2022 10:29 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of CareDx, Inc. - CDNA
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of CareDx, Inc. (NasdaqGM: CDNA), if they purchased the Company’s shares between shares between February 24, 2021 and May 5, 2022, inclusive (the “Class...
Jul 06, 2022 11:45 am ET
DEADLINE ALERT for CDNA, SPRO, and LMPX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 06, 2022 01:30 am ET
CareDx, Inc. (NASDAQ: CDNA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against CareDx
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Jul 05, 2022 10:50 pm ET
CAREDX SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against CareDx, Inc. - CDNA
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 22, 2022 to file lead plaintiff applications in a securities class action lawsuit against CareDx, Inc. (“CareDx” or the “Company”) (NasdaqGM: CDNA), if...
Jul 05, 2022 05:47 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages CareDx (CDNA) Investors with Significant Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Fraud Class Action
Hagens Berman urges CareDx, Inc. (NASDAQ: CDNA) investors to with significant losses to submit your losses now. Class Period: Feb. 24, 2021 – May 5, 2022Lead Plaintiff Deadline: July 22, 2022Visit: www.hbsslaw.com/investor-fraud/CDNA Contact An...
Jul 05, 2022 01:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CareDx, Inc. (CDNA)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 22, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired CareDx, Inc. (“CareDx” or the...
Jul 05, 2022 10:36 am ET
ENSV, CDNA & AllianzGI Class Action Deadlines: Bronstein, Gewirtz & Grossman, LLC, A Leading Class Action Firm, Reminds Investors to Contact the Firm and Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jul 04, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CareDx, Inc. (NASDAQ: CDNA), Spero Therapeutics, Inc. (NASDAQ: SPRO), LMP...
Jul 03, 2022 06:26 am ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages CareDx, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important July 22 Deadline in Securities Class Action – CDNA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CareDx, Inc. (NASDAQ: CDNA) between February 24, 2021 and May 5, 2022, both dates inclusive (the “Class Period”), of the important July 22, 2022 lead...
Jul 02, 2022 06:54 pm ET
Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds CareDx, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors to Contact the Firm
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against CareDx, Inc. (“CareDx”)...
Jul 01, 2022 12:32 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CareDx, Inc. – CDNA
Pomerantz LLP is investigating claims on behalf of investors of CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA). Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980. The...
Jun 30, 2022 01:50 pm ET
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That Securities Class Action Lawsuits Have Been Filed on Behalf of Investors in APYX Medical Corporation (APYX), CareDx, Inc. (CDNA), and Verrica
The law firm of Kirby McInerney LLP reminds investors that securities class action lawsuits have been filed on behalf of investors in securities of APYX Medical Corporation, CareDx, Inc., and Verrica Pharmaceuticals, Inc. Investors have until the...
Jun 30, 2022 12:00 pm ET
DEADLINE ALERT for CDNA, SPRO, LMPX, IONQ: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 30, 2022 05:45 am ET
CDNA LAWSUIT ALERT: Levi & Korsinsky Notifies CareDx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, June 30, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA) of a class action securities lawsuit.
Jun 29, 2022 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of CareDx, Inc. - CDNA
CEDARHURST, N.Y., June 29, 2022 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of CareDx, Inc. (NasdaqGM: CDNA), if they purchased the Company's shares between shares between February 24, 2021 and May 5, 2022, inclusive (the "Class Period"). Shareholders have until July 22, 2022 to file lead plaintiff applications in the securities class action lawsuit.
Jun 29, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CareDx, Inc. (NASDAQ: CDNA), Spero Therapeutics, Inc. (NASDAQ: SPRO), LMP...
Jun 29, 2022 05:58 pm ET
CareDx, Inc. (NASDAQ: CDNA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against CareDx
Did you lose money on investments in CareDx? If so, please visit CareDx, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
Jun 29, 2022 12:15 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of CareDx, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 22, 2022 - (NASDAQ: CDNA)
NEW YORK, June 29, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of CareDx, Inc..
Jun 29, 2022 11:45 am ET
DEADLINE ALERT for CDNA, SPRO, and LMPX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 29, 2022 09:43 am ET
CDNA DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages CareDx (CDNA) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Pending
Hagens Berman urges CareDx, Inc. (NASDAQ: CDNA) investors to with significant losses to submit your losses now. Class Period: Feb. 24, 2021 – May 5, 2022Lead Plaintiff Deadline: July 22, 2022Visit: www.hbsslaw.com/investor-fraud/CDNAContact An...
Jun 28, 2022 10:50 pm ET
CAREDX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Car
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2022 to file lead plaintiff applications in a securities class action lawsuit against CareDx,...
Jun 28, 2022 12:00 pm ET
CareDx, Inc. (NASDAQ: CDNA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against CareDx
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Jun 28, 2022 07:01 am ET
CareDx Lead Sponsor for 2022 Donate Life Transplant Games
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its participation and presenting sponsorship for the 2022 Donate Life Transplant Games taking place July 29 to August 3, 2022, in San Diego, California. CareDx’s transplant patient health app, AlloCare®, is the official app for the Games.
Jun 28, 2022 05:45 am ET
CDNA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 22, 2022 in the Class Action Filed on Behalf of CareDx, Inc. Shareholders
NEW YORK , June 28, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CareDx, Inc. (NASDAQ: CDNA) alleging that the Company violated federal securities laws.
Jun 27, 2022 10:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CareDx, Inc. - CDNA
NEW YORK, June 27, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jun 27, 2022 04:30 pm ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind CareDx Investors of a Lead Plaintiff Deadline of July 22, 2022
NEW YORK, June 27, 2022 /PRNewswire/ -- Attention CareDx, Inc. ("CareDx") (NASDAQ: CDNA) shareholders:
Jun 27, 2022 11:00 am ET
CDNA Investors Have Opportunity to Lead CareDx, Inc. Securities Fraud Lawsuit
BENSALEM, Pa., June 27, 2022 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA).
Jun 27, 2022 11:00 am ET
CDNA Investors Have Opportunity to Lead CareDx, Inc. Securities Fraud Lawsuit
BENSALEM, Pa., June 27, 2022 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA).
Jun 27, 2022 10:24 am ET
CareDx, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
The Portnoy Law Firm advises CareDx, Inc. (NASDAQ: CDNA) investors that a class action filed on behalf of investors. CareDx investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to...
Jun 27, 2022 09:03 am ET
CDNA DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP - Important July 22, 2022 Deadline Reminder for CareDx, Inc.
RADNOR, Pa., June 27, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against CareDx, Inc. ("CareDx") (NASDAQ: CDNA). The action charges CareDx with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.  As a result of CareDx's materially misleading statements and omissions to the public, CareDx's investors have suffered significant losses.
Jun 25, 2022 04:00 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages CareDx, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – CDNA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CareDx, Inc. (NASDAQ: CDNA) between February 24, 2021 and May 5, 2022, both dates inclusive (the “Class Period”), of the important July 22, 2022 lead...
Jun 24, 2022 10:50 pm ET
CAREDX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Car
NEW ORLEANS, June 24, 2022 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2022 to file lead plaintiff applications in a securities class action lawsuit against CareDx, Inc. ("CareDx" or the "Company") (NasdaqGM: CDNA), if they purchased the Company's shares between February 24, 2021 and May 5, 2022, inclusive (the "Class Period").  This action is pending in the United States District Court for the Northern District of California.
Jun 24, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Enservco, CareDx, Spero, and LMP Automotive and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Enservco Corp. (NYSE American: ENSV), CareDx, Inc. (NASDAQ: CDNA), Spero...
Jun 24, 2022 07:50 pm ET
CareDx, Inc. (NASDAQ: CDNA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against CareDx
Did you lose money on investments in CareDx? If so, please visit CareDx, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
Jun 24, 2022 12:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CareDx, Inc. (CDNA)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 22, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired CareDx, Inc. (“CareDx” or the...
Jun 24, 2022 09:45 am ET
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of CareDx, Inc. (CDNA) Investors and Encourages Investors to Contact the Firm Before July 22, 2022
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired CareDx, Inc. (“CareDx”) (NASDAQ: CDNA) securities from...
Jun 24, 2022 09:11 am ET
Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against CareDx, Inc. (CDNA)
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against CareDx, Inc. (“CareDx”)...
Jun 24, 2022 05:45 am ET
CDNA SHAREHOLDER ALERT: Jakubowitz Law Reminds CareDx Shareholders of a Lead Plaintiff Deadline of July 22, 2022
NEW YORK, June 24, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of CareDx, Inc. (NASDAQ: CDNA).
Jun 23, 2022 04:20 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages CareDx (CDNA) Investors with Significant Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Fraud Class Action
Hagens Berman urges CareDx, Inc. (NASDAQ: CDNA) investors to with significant losses to submit your losses now. Class Period: Feb. 24, 2021 – May 5, 2022Lead Plaintiff Deadline: July 22, 2022Visit: www.hbsslaw.com/investor-fraud/CDNA Contact An...
Jun 23, 2022 03:43 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CareDx, Inc. – CDNA
Pomerantz LLP is investigating claims on behalf of investors of CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA). Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980. The...
Jun 23, 2022 02:00 pm ET
CDNA Investors Have Opportunity to Lead CareDx, Inc. Securities Fraud Lawsuit
LOS ANGELES, June 23, 2022 /PRNewswire/ --The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA).
Jun 23, 2022 08:00 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in CareDx, Inc with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 23, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CareDx, Inc ("CareDx" or "the Company") (NASDAQ:CDNA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jun 23, 2022 05:45 am ET
CDNA LAWSUIT ALERT: Levi & Korsinsky Notifies CareDx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, June 23, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA) of a class action securities lawsuit.
Jun 22, 2022 10:46 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of CareDx, Inc. - CDNA
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of CareDx, Inc. (NasdaqGM: CDNA), if they purchased the Company’s shares between shares between February 24, 2021 and May 5, 2022, inclusive (the “Class...
Jun 22, 2022 06:08 pm ET
Kaplan Fox Investigates Potential Securities Fraud at CareDx
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA), a diagnostics company that provides services and products to the organ transplant recipient...
Jun 22, 2022 12:30 pm ET
CareDx, Inc. (NASDAQ: CDNA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against CareDx
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Jun 22, 2022 11:47 am ET
DEADLINE ALERT for CDNA, SPRO, and LMPX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 22, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of CareDx, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 22, 2022 - (NASDAQ: CDNA)
NEW YORK, June 22, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of CareDx, Inc..
Jun 21, 2022 10:43 pm ET
CAREDX SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against CareDx, Inc. - CDNA
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 22, 2022 to file lead plaintiff applications in a securities class action lawsuit against CareDx, Inc. (“CareDx” or the “Company”) (NasdaqGM: CDNA), if...
Jun 21, 2022 12:00 pm ET
DEADLINE ALERT for CDNA, SPRO, LMPX, IONQ: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 21, 2022 12:00 pm ET
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in CareDx, Inc with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 21, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CareDx, Inc ("CareDx" or "the Company") (NASDAQ:CDNA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jun 21, 2022 07:01 am ET
CareDx The Transplant Company Releases Inaugural Environmental, Social and Governance Report
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the release of its first environmental, social and governance (ESG) report.
Jun 21, 2022 05:45 am ET
CDNA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 22, 2022 in the Class Action Filed on Behalf of CareDx, Inc. Shareholders
NEW YORK, June 21, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CareDx, Inc. (NASDAQ: CDNA) alleging that the Company violated federal securities laws.
Jun 20, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind CareDx Investors of a Lead Plaintiff Deadline of July 22, 2022
NEW YORK, June 20, 2022 /PRNewswire/ -- Attention CareDx, Inc. ("CareDx") (NASDAQ: CDNA) shareholders:
Jun 20, 2022 01:24 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CareDx, Inc. - CDNA
NEW YORK, June 20, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jun 19, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP Auto, and Dentsply Sirona and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CareDx, Inc. (NASDAQ: CDNA), Spero Therapeutics, Inc. (NASDAQ: SPRO), LMP...
Jun 19, 2022 08:00 pm ET
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages CareDx, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – CDNA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CareDx, Inc. (NASDAQ: CDNA) between February 24, 2021 and May 5, 2022, both dates inclusive (the “Class Period”), of the important July 22, 2022 lead...
Jun 18, 2022 03:33 pm ET
CLASS ACTION NOTICE: Kessler Topaz Meltzer & Check, LLP Reminds CareDx, Inc. Shareholders of Securities Fraud Class Action Lawsuit
RADNOR, Pa., June 18, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against CareDx, Inc. ("CareDx") (NASDAQ: CDNA). The action charges CareDx with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.  As a result of CareDx's materially misleading statements and omissions to the public, CareDx's investors have suffered significant losses.
Jun 17, 2022 10:50 pm ET
CAREDX SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against CareDx, Inc. - CDNA
NEW ORLEANS, June 17, 2022 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 22, 2022 to file lead plaintiff applications in a securities class action lawsuit against CareDx, Inc. ("CareDx" or the "Company") (NasdaqGM: CDNA), if they purchased the Company's shares between February 24, 2021 and May 5, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of California.
Jun 17, 2022 04:55 pm ET
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of CareDx, Inc. (CDNA) Investors and Encourages Investors to Contact the Firm Before July 22, 2022
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired CareDx, Inc. (“CareDx”) (NASDAQ: CDNA) securities from February 24, 2021 through May 5, 2022, both dates inclusive (the “Class Perio
Jun 17, 2022 05:45 am ET
CDNA SHAREHOLDER ALERT: Jakubowitz Law Reminds CareDx Shareholders of a Lead Plaintiff Deadline of July 22, 2022
NEW YORK, June 17, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of CareDx, Inc. (NASDAQ: CDNA).
Jun 16, 2022 08:17 pm ET
Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against CareDx, Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against CareDx, Inc. (“CareDx”)...
Jun 16, 2022 01:00 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in CareDx, Inc with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 16, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CareDx, Inc ("CareDx" or "the Company") (NASDAQ:CDNA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jun 16, 2022 11:45 am ET
DEADLINE ALERT for CDNA, SPRO, and LMPX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 16, 2022 05:45 am ET
CDNA LAWSUIT ALERT: Levi & Korsinsky Notifies CareDx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, June 16, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA) of a class action securities lawsuit.
Jun 15, 2022 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of CareDx, Inc. - CDNA
CEDARHURST, N.Y., June 15, 2022 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of CareDx, Inc. (NasdaqGM: CDNA), if they purchased the Company's shares between shares between February 24, 2021 and May 5, 2022, inclusive (the "Class Period"). Shareholders have until July 22, 2022 to file lead plaintiff applications in the securities class action lawsuit.
Jun 15, 2022 08:10 pm ET
CareDx, Inc. Investor News: Robbins LLP is Investigating CareDx, Inc. (CDNA) on Behalf of Shareholders
Shareholder rights law firm Robbins LLP is investigating CareDx, Inc. (NASDAQ: CDNA) and its officers and directors to determine if they breached their fiduciary duties and violated securities laws by engaging in improper schemes to inflate revenue. CareDx is a diagnostics company that provides services and products to the organ transplant

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.